ENTITY

Targovax AS (TRVX NO)

10
Analysis
Health CareNorway
Targovax AS develops biopharmaceutics. The Company specializes in creation of therapeutic vaccines for various types of cancer. Targovax serves the healthcare sector.
more
bullishTargovax AS
17 Sep 2020 17:32Issuer-paid

Targovax - Growing list of collaborations and more data in H2

An update from Targovax’s Phase I/II study in unresectable mesothelioma with OCOS-102 was the highlight of Q220 (described in our last note)....

Share
bullishTargovax AS
22 Jun 2020 23:14Issuer-paid

Targovax - Confirmatory 12-month mesothelioma update

On 22 June 2020 Targovax reported data from its Phase I/II study in unresectable mesothelioma (a follow up to the first data published in January...

Share
bullishTargovax AS
28 May 2020 19:04Issuer-paid

Targovax - ONCOS-102 plus durvalumab trial in spotlight

Targovax has announced that one of the trials with ONCOS-102, which is sponsored by Ludwig Institute for Cancer Research, will be in the spotlight...

Share
bullishTargovax AS
23 Mar 2020 19:12Issuer-paid

Targovax - More data in 2020 from both clinical trials

Targovax started 2020 with the first randomised data readout from its Phase I/II trial with oncolytic virus ONCOS-102 in unresectable mesothelioma....

Share
bullishTargovax AS
27 Jan 2020 17:57Issuer-paid

Targovax - ONCOS-102 set for late-stage development

Together with the positive Phase I/II mesothelioma trial, Targovax has introduced a preliminary design for its next trial. The new study will...

Share
No more insights
x